LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 81ST LEGISLATIVE REGULAR SESSION May 15, 2009 TO: Honorable Joe Straus, Speaker of the House, House of Representatives FROM: John S. O'Brien, Director, Legislative Budget Board IN RE:HB1672 by Crownover (Relating to newborn screening.), As Passed 2nd House No significant fiscal implication to the State is anticipated. The bill would add sickle cell trait to the newborn screening program. The bill would define any report, record, and information relating to newborn screening as confidential and not subject to subpoena or disclosure, except as provided by the bill. The records may be disclosed for purposes of diagnosis, a court order, a medical examiner conducting an autopsy on a child, and for certain public health research purposes under certain circumstances. Reports, records and information that does not identify the child or the family of the child may be released without consent for statistical purposes, quality assurance testing, and research purposes. The bill would require a disclosure statement to be developed by the Department of State Health Services (DSHS). The disclosure statement would inform the parent, managing conservator, or guradian that they may limit the use of genetic material by providing a written statement prohibiting the department or laboratory from retaining the genetic material or using it for other purposes. DSHS or an approved laboratory would still conduct the newborn screening test. The bill would require a committee of legislative members to study newborn screening and submit a report no later than December 15, 2010 to both houses of the legislature. The bill would take effect immediately upon a two-thirds vote of each house; if it does not receive the vote necessary for immediate effect, the bill would take effect September 1, 2009. The additional testing would not be a new cost to the agency because the current screening identifies sickle cell trait. It is assumed that new procedures identified in the bill and the study of newborn screening can be absorbed within existing resources. Local Government Impact No fiscal implication to units of local government is anticipated. Source Agencies:537 State Health Services, Department of LBB Staff: JOB, SD, CL, BM, MB
LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 81ST LEGISLATIVE REGULAR SESSION
May 15, 2009
TO: Honorable Joe Straus, Speaker of the House, House of Representatives FROM: John S. O'Brien, Director, Legislative Budget Board IN RE:HB1672 by Crownover (Relating to newborn screening.), As Passed 2nd House
TO: Honorable Joe Straus, Speaker of the House, House of Representatives
FROM: John S. O'Brien, Director, Legislative Budget Board
IN RE: HB1672 by Crownover (Relating to newborn screening.), As Passed 2nd House
Honorable Joe Straus, Speaker of the House, House of Representatives
Honorable Joe Straus, Speaker of the House, House of Representatives
John S. O'Brien, Director, Legislative Budget Board
John S. O'Brien, Director, Legislative Budget Board
HB1672 by Crownover (Relating to newborn screening.), As Passed 2nd House
HB1672 by Crownover (Relating to newborn screening.), As Passed 2nd House
No significant fiscal implication to the State is anticipated.
No significant fiscal implication to the State is anticipated.
The bill would add sickle cell trait to the newborn screening program. The bill would define any report, record, and information relating to newborn screening as confidential and not subject to subpoena or disclosure, except as provided by the bill. The records may be disclosed for purposes of diagnosis, a court order, a medical examiner conducting an autopsy on a child, and for certain public health research purposes under certain circumstances. Reports, records and information that does not identify the child or the family of the child may be released without consent for statistical purposes, quality assurance testing, and research purposes. The bill would require a disclosure statement to be developed by the Department of State Health Services (DSHS). The disclosure statement would inform the parent, managing conservator, or guradian that they may limit the use of genetic material by providing a written statement prohibiting the department or laboratory from retaining the genetic material or using it for other purposes. DSHS or an approved laboratory would still conduct the newborn screening test. The bill would require a committee of legislative members to study newborn screening and submit a report no later than December 15, 2010 to both houses of the legislature. The bill would take effect immediately upon a two-thirds vote of each house; if it does not receive the vote necessary for immediate effect, the bill would take effect September 1, 2009. The additional testing would not be a new cost to the agency because the current screening identifies sickle cell trait. It is assumed that new procedures identified in the bill and the study of newborn screening can be absorbed within existing resources.
The bill would add sickle cell trait to the newborn screening program. The bill would define any report, record, and information relating to newborn screening as confidential and not subject to subpoena or disclosure, except as provided by the bill. The records may be disclosed for purposes of diagnosis, a court order, a medical examiner conducting an autopsy on a child, and for certain public health research purposes under certain circumstances. Reports, records and information that does not identify the child or the family of the child may be released without consent for statistical purposes, quality assurance testing, and research purposes.
The bill would require a disclosure statement to be developed by the Department of State Health Services (DSHS). The disclosure statement would inform the parent, managing conservator, or guradian that they may limit the use of genetic material by providing a written statement prohibiting the department or laboratory from retaining the genetic material or using it for other purposes. DSHS or an approved laboratory would still conduct the newborn screening test.
The bill would require a committee of legislative members to study newborn screening and submit a report no later than December 15, 2010 to both houses of the legislature.
The bill would take effect immediately upon a two-thirds vote of each house; if it does not receive the vote necessary for immediate effect, the bill would take effect September 1, 2009.
The additional testing would not be a new cost to the agency because the current screening identifies sickle cell trait. It is assumed that new procedures identified in the bill and the study of newborn screening can be absorbed within existing resources.
Local Government Impact
No fiscal implication to units of local government is anticipated.
Source Agencies: 537 State Health Services, Department of
537 State Health Services, Department of
LBB Staff: JOB, SD, CL, BM, MB
JOB, SD, CL, BM, MB